Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and raises the price tar

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the pri

Bruker CorporationCommon StockPreferred StockDebt SecuritiesWarrantsUnitsDepositary SharesSubscripti

At ASM Microbe 2026, Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostic

Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry

World's highest-field MRI system provides leading disease biology research capabilitiesBruker Co

UBS analyst Dan Leonard maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the p

TD Cowen analyst Kyle Boucher maintains Bruker (NASDAQ:BRKR) with a Hold and raises the price tar

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the pri

Bruker (NASDAQ:BRKR) affirms FY2026 Adj EPS guidance from $2.10-$2.15 to $2.10-$2.15 vs $2.12 analys

Bruker (NASDAQ:BRKR) reported quarterly earnings of $0.31 per share which beat the analyst consensus

MALDI Biotyper® (MBT): Launch of proprietary MBT Easy T® Kit for consistent sample transfer to MALDI

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and lowers the pri

The introductions span console electronics, quantitative chemistry, benchtop FT-NMR, solid-state and

Bruker Corporation (NASDAQ:BRKR) today announced accelerated development of its photothermal AFM-IR

Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and lowers the price tar

Novel timsOmni workflows enable deeper functional characterization of proteoforms and PTMs, leveragi

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Neutral and lowers the p

Goldman Sachs analyst Evie Koslosky maintains Bruker (NASDAQ:BRKR) with a Sell and lowers the pri

TD Cowen analyst Dan Brennan maintains Bruker (NASDAQ:BRKR) with a Hold and lowers the price targ

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and lowers the pri

Bruker (NASDAQ:BRKR) is looking for FY2026 Adj EPS of $2.10-$2.15 vs $2.13 analyst estimate. sees sa

Bruker (NASDAQ:BRKR) reported quarterly earnings of $0.59 per share which missed the analyst consens

Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and raises the price tar

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the p

Wall Street traded timidly on Tuesday despite another benign inflation report that reinforced expect

Item 2.02 Results of Operations and Financial Condition. On January 12, 2026, during its scheduled p

Bruker BEST division announced $500M supply deals with global radiology companies for advanced super

TD Cowen analyst Dan Brennan maintains Bruker (NASDAQ:BRKR) with a Hold and raises the price targ

Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and raises the price tar

RI Research Instruments, a company that is majority-owned by Bruker Corporation (NASDAQ:BRKR), today

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the pri

JP Morgan analyst Casey Woodring maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the

Wells Fargo analyst Brandon Couillard maintains Bruker (NASDAQ:BRKR) with a Overweight and raises

B of A Securities analyst Derik De Bruin maintains Bruker (NASDAQ:BRKR) with a Buy and raises the

Wolfe Research analyst Doug Schenkel upgrades Bruker (NASDAQ:BRKR) from Peer Perform to Outperfor

Goldman Sachs analyst Evie Koslosky initiates coverage on Bruker (NASDAQ:BRKR) with a Sell rating

Indaba Capital Management, L.P. ("Indaba"), controlling shareholder of AST Revolution, LLC (

Rothschild & Co analyst Natalya Davies initiates coverage on Bruker (NASDAQ:BRKR) with a Buy